Tumor-host interactions in the gallbladder suppress distal angiogenesis and tumor growth: Involvement of transforming growth factor β1

Nature Medicine

Volumn 5, Issue 10, 1999, Pages 1203-1208

  Gohongi, Takeshi ^a   Fukumura, Dai ^a   Boucher, Yves ^a   Yun, Chae Ok ^a   Soff, Gerald A ^b   Compton, Carolyn ^a   Todoroki, Takeshi ^c   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; TRANSFORMING GROWTH FACTOR BETA1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL DIAMETER; CANCER INHIBITION; CELL INTERACTION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GALLBLADDER TUMOR; GROWTH RATE; HOST RESISTANCE; LEUKOCYTE ADHERENCE; LEUKOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

ANGIOSTATINS; ANIMALS; BRAIN NEOPLASMS; CARCINOMA; GALLBLADDER NEOPLASMS; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PLASMINOGEN; SKULL; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA;

EID: 0032846119     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/13524     Document Type: Article

References (25)

1. O'Reilly, M.S. et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastasis by a lewis lung carcinoma. Cell. 79 315-328 (1994).
2. Volpert, O.V., Lawler, J. & Bouck, N.P. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastasis via thrombospondin-1. Proc. Natl. Acad Sci. USA 95, 6343-6348 (1998).
3. Dellian, M., Witwer, B.P., Salehi, H.A., Yuan, F. & Jain, R.K. Quantitation and physiological characterization of angiogenic vessels in mice: Effect of basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and host microenvironment. Am. J. Pathol. 149, 59-72 (1996).
4. Fidler, I.J. Modulation of the organ microenvironment for treatment of cancer metastasis. J. Natl. Cancer Inst. 87, 1588-1592 (1995).
5. Sckell, A., Safabakhsh, N., Dellian, M. & Jain, R.K. Primary tumor size-dependent inhibition of angiogenesis at a secondary site: An intravital microscopic study in mice. Cancer Res. 58, 5866-5869 (1998).
6. Robert, B.V. & Sage, E.H. A novel, quantitative model for study of endothelial cell migration and sprout formation within three-dimensional collagen matrices. Microvascular Res. 57, 118-133 (1999).
7. Müller, G., Behrens, J., Nussbaumer, U., Böhlen, P. & Birchmeier, W. Inhibitory action of transforming growth factor β on endothelial cells. Proc. Natl. Acad. Sci. USA 84, 5600-5604 (1987).
8. Pepper, M.S., Vassalli, J.D., Orci, L. & Montesnano, R. Biphasic effect of transforming growth factor-β1 on in vitro angiogenesis. Exp. Cell. Res. 204, 356-363 (1993).
9. Gajdusek, C.M., Luo, Z. & Mayberg, M.R. Basic fibroblast growth factor and Transforming growth factor beta-1 : Synergistic mediators of angiogenesis in vitro. J. Cell. Phys. 157, 133-134 (1993).
10. Pepper, M.S. Transforming growth factor-beta: Vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev. 8, 21-43 (1997).
11. Yang, E.Y. & Moses, H.L. Transforming growth factor β1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J. Cell Biol. 111, 731-741 (1990).
12. Fajardo, L.F., Prionas, S.D., Kwan, H.H., Kowalski, J. & Allison, A.C. Transforming growth factor β1 induces angiogenesis in vivo with a threshold pattern. Lab. Invest. 74, 600-608 (1996).
13. Ito, N. et al. Positive correlation of plasma transforming growth factor-beta1 levels with tumor vascularity in hepatocellular carcinoma. Cancer Lett. 89, 45-48 (1995).
14. Wikstrom, P., Stattin, P., Franck-Lissbrant, I., Damber, J.E. & Bergh, A. Transforming growth factor β1 is associated with angiogenesis, metastasis and poor clinical outcome in prostate cancer. Prostate 37, 19-29 (1998).
15. Ueki, N. et al. Excessive production of transforming grwoth-factorβ1 can play an important role in the development of tumorigenesis by its action for angiogenesis: validity of neutralizing antibodies to block tumor growth. Biochim. Biophys. Acta 1137, 189-196 (1992).
16. Engle, S.J. et al. Transforming growth factorβ1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res. 59, 3379-3386 (1999).
17. Norgaard, P., Hougaard, S., Poulsen, H.S. & Spang-Thomsen, M. Transforming growth factor β and cancer. Cancer Treat. Rev. 21, 367-403 (1995).
18. Theodorescu, D., Caltabiano, M., Greig, R., Rieman, D. & Kerbel, R.S. Reduction of TGF beta activity abrogates growth promoting tumor cell-cell interactions in vivo. J. Cell. Phys. 148, 380-390 (1991).
19. Carmeliet, P. et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394, 485-490 (1998).
20. Gamble, J.R., Khew-Goodall, Y. & Vadas, M.A. Transforming growth factor-β inhibits E-selectin expression on human endothelial cells. J. Immunol. 150, 4494-4503 (1993).
21. Walker, R.A. & Dearing, S.J. Transforming growth factor β1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur. J. Cancer 28, 641-644 (1992).
22. Nakanishi, Y. et al. The expression of vascular endothelial growth factor and transforming growth factor-β associates with angiogenesis in epithelial ovarian cancer. Int. J. Gynecol. Pathol. 16, 256-262 (1997).
23. Picon, A., Gold, L.I., Wang, J., Cohen, A. & Friedman, E. A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor β1. Cancer Epidemiol. Biomarkers Prev. 7, 497-504 (1988).
24. Todoroki, T. et al. Resection combined with intraoperative radiation therapy (IORT) for stage IV (TNM) gallbladder carcinoma. World J. Surg. 15, 357-366 (1991).
25. Jain, R.K., Schlenger, K., Hockel, M. & Yuan, F. Quantitative angiogenesis assays: progress and problems. Nature Med. 3, 1203-1208 (1997).